Success is in the Air for Lou Bock
▶
Share this post:
Facebook |
Twitter |
Google+ |
LinkedIn |
Pinterest |
Reddit |
Email
This post can be linked to directly with the following short URL:
The audio player code can be adjusted to different sizes:
The audio player code can be used without the image as follows:
This audio file can be linked to by copying the following URL:
Right/Ctrl-click to download the audio file.
Subscribe:
Connected Social Media -
iTunes |
Spotify |
YouTube |
Twitter |
RSS Feed
It’s August 2009 and in the last 12 months, Lou Bock‘s portfolio has had some impressive success. He talks about how Zogenix, Horizon Therapeutics, Somaxon, Prestwick Pharmaceuticals and Orexigen have all done well. The Scale Venture Partners Managing Director has seen two positive Phase III outcomes, 2 FDA approvals and one progressing to approval since August 2008.
Tags:
biopharmaceutical, emerging biopharmaceutical devices, FDA, Horizon Therapeutics, Lou Bock, Orexigen, Prestwick Pharmaceuticals, Scale Venture Partners, Somaxon, Zogenix
Posted in:
Audio Podcast, Healthcare, Venture Perspectives by Scale Venture Partners
